Clinical experience with monoclonal antibodies to epidermal growth factor receptor

被引：18

作者：

Calvo E. ^{[1
]}

Rowinsky E.K. ^{[1
]}

机构：

[1] Institute for Drug Development, Cancer Therapy and Research Center, University of Texas, San Antonio, TX 78229

来源：

Current Oncology Reports | 2005年 / 7卷 / 2期

关键词：

Epidermal Growth Factor Receptor; Cetuximab; Epidermal Growth Factor Receptor Expression; Panitumumab; Proc ASCO;

D O I：

10.1007/s11912-005-0034-9

中图分类号：

学科分类号：

摘要：

Recent knowledge about the intermediate steps and final consequences of ligand-dependent epidermal growth factor receptor (EGFR) activation has clearly supported the notion that EGFR plays a fundamental role in regulating the proliferation and survival of malignant neoplasms. Among the rationally designed target-based therapeutics that are being assessed, those targeting EGFR appear to be some of the most clinically relevant. The strategy of using monoclonal antibodies (mAbs) to block ligand binding to the extracellular domain of the EGFR has led to the development of therapeutics that robustly arrest malignant cell proliferation and, in some cases, induce profound tumor regression. The chimeric mAb against EGFR, cetuximab, has already been approved by regulatory agencies worldwide to treat patients with advanced colorectal cancer. Other mAbs against EGFR, particularly panitumumab (ABX-EGF), h-R3, and EMD72000, are in advanced stages of clinical development. Copyright © 2005 by Current Science Inc.

引用

页码：96 / 103

页数：7

共 58 条

[1] Baselga J., Why the epidermal growth factor receptor? The rationale for cancer therapy, Oncologist, 7, SUPPL. 4, pp. 2-8, (2002)
[2] Rowinsky E.K., The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors, Annu. Rev. Med., 55, pp. 433-457, (2004)
[3] Rowinsky E., Targeting signal transduction. The erbB receptor family as a target for therapeutic development against cancer, Signal Transduction Inhibitors, pp. 3-36, (2001)
[4] Mendelsohn J., Targeting the epidermal growth factor receptor for cancer therapy, J. Clin. Oncol., 20, (2002)
[5] Baselga J., Albanell J., Molina M.A., The ErbB receptor family: A therapeutic target for cancer, Trends Mol. Med., 8, (2004)
[6] Arteaga C.L., Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia, Semin. Oncol., 29, pp. 3-9, (2002)
[7] Mendelsohn J., Baselga J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J. Clin. Oncol., 21, pp. 2787-2799, (2003)
[8] Mazure N.M., Chen E.Y., Laderoute K.R., Giaccia A.J., Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element, Blood, 90, pp. 3322-3331, (1997)
[9] Jung Y.D., Nakano K., Liu W., Et al., Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells, Cancer Res., 59, pp. 4804-4807, (1999)
[10] Baselga J., Albanell J., Epithelial growth factor receptor interacting agents, Hematol. Oncol. Clin. North Am., 16, pp. 1041-1063, (2002)

← 1 2 3 4 5 6 →